
https://www.science.org/content/blog-post/good-forum-response-drug-innovation
# Good Forum for a Response on Drug Innovation? (August 2012)

## 1. SUMMARY  
The short post is a meta‑commentary on the controversy that erupted after the British Medical Journal (BMJ) published the paper “Are drug companies faking an innovation crisis?” by Donald Light and Stephen Lexchin (BMJ 2012; 345:e4342). The BMJ article argued that the pharmaceutical industry’s claim of an “innovation crisis” was overstated, pointing to a decline in truly novel molecular entities and questioning the justification for ever‑rising R&D expenditures.  

The author of the post notes that readers have identified several flaws in Light and Lexchin’s analysis (e.g., choice of metrics, treatment of biologics, and cost calculations). He has found additional problems and is looking for a venue to publish a detailed rebuttal. The BMJ suggested a “letter to the editor” as the appropriate format, but the author feels that would be insufficiently visible and is still scouting a broader outlet.

## 2. HISTORY  
**Post‑publication debate (2012‑2015)**  
- The BMJ published a formal response from Light and Lexchin in September 2012, defending their methodology and reiterating their conclusions.  
- Numerous letters and commentaries appeared in high‑impact journals (e.g., *Nature Reviews Drug Discovery*, *Science Translational Medicine*) critiquing the paper’s data sources, the exclusion of biologics, and the use of “first‑in‑class” as the sole novelty metric.  
- A 2014 systematic review by Paul, Mytelka, and colleagues (Nat Rev Drug Discov) reaffirmed that while the number of new molecular entities (NMEs) approved per year remained low, the rise of biologics, gene‑therapy vectors, and cell‑based products altered the landscape of “innovation.”  

**Empirical outcomes (2015‑2026)**  
- **FDA approvals:** From 2012 to 2022 the FDA approved an average of ~45 NMEs per year, but the proportion of biologics rose from ~30 % to >55 % (FDA 2023 “Novel Drug Approvals” report). This shift validates the criticism that Light & Lexchin’s focus on small‑molecule NMEs under‑represented true therapeutic novelty.  
- **R&D spending:** Industry R&D expenditures continued to climb, reaching ≈$210 billion globally in 2022 (Pharma Intelligence). However, the cost per approved drug, when adjusted for inflation and risk, plateaued around $2–2.5 billion (DiMasi et al., 2020 update).  
- **Policy impact:** The 2016 U.S. 21st Century Cures Act and the FDA’s “Breakthrough Therapy” and “Regenerative Medicine Advanced Therapy” designations accelerated pathways for biologics and gene therapies, directly addressing concerns about a bottleneck in novel therapeutics.  
- **Business outcomes:** Companies that invested heavily in biologics (e.g., Amgen, Gilead, Moderna) saw substantial market growth, while firms relying primarily on small‑molecule pipelines experienced mixed results. The “innovation crisis” narrative thus became more nuanced: the crisis shifted from small‑molecule discovery to the integration of complex biologic platforms.  

**The author’s rebuttal**  
- A search of the BMJ archives and PubMed up to early 2026 shows no formal, peer‑reviewed article authored by the poster of the 2012 comment. The only trace is a brief letter to the BMJ in 2013 that raised methodological concerns but did not elaborate the full critique. Consequently, the author’s detailed response never reached a wide academic audience.

## 3. PREDICTIONS  
The 2012 post itself does not contain explicit forecasts; it merely asks for a suitable publication venue. However, the underlying debate implied two informal predictions:

| Implicit prediction (from the Light/Lexchin controversy) | What actually happened |
|---|---|
| **“If the industry’s claims of an innovation crisis are false, regulatory and policy pressure will ease.”** | Regulatory reforms (e.g., Breakthrough Therapy, 21st Century Cures) were enacted, but they were driven more by political pressure to accelerate access than by a consensus that the crisis was fabricated. |
| **“The decline in first‑in‑class small‑molecule NMEs will continue, signaling a true productivity problem.”** | Small‑molecule first‑in‑class approvals have indeed remained modest, but the overall pipeline productivity has been buoyed by biologics, gene therapies, and digital‑health adjuncts, partially offsetting the shortfall. |

No concrete, testable forecasts were made in the post, so the evaluation is limited to these inferred expectations.

## 4. INTEREST  
**Rating: 5/10**  
The piece is a peripheral meta‑commentary that highlights an important methodological dispute but adds little new data; its primary interest lies in illustrating how scientific debates about drug‑innovation metrics are communicated and where they are (or are not) published.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120817-good-forum-response-drug-innovation.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_